title: [Dynamics of cognitive and emotional-volitional disorders in children and adolescents with refractory epilepsy during the treatment with levetiracetam].
abstract: We examined 76 children and adolescents (45 boys (59.2%), 31 girls (40.8%), aged from 6 to 17 years (mean age 14.31 ± 0.3), with the diagnosis of refractory epilepsy using a clinical/psychopathological method and psychometric scales. Marked non-psychotic mental disorders of varying severity were observed in all patients. The patients were treated with levetiracetam in a dose of 60 mg/kg/day during one year. The reduction in the frequency of epileptic seizures was achieved in 77.6% of patients. The significant (p<0.01) improvement in cognitive functions and speech were found in 81.6% cases. The treatment reduced stress and improved mood in 63.1% of patients.
authors.forename: Iu V
authors.initials: IuV
authors.lastname: Popov
authors.forename: Iu A
authors.initials: IuA
authors.lastname: Iakovleva
mesh_terms: D000293:Adolescent; D000342:Affective Symptoms / Q000188:drug therapy / Q000209:etiology* / Q000503:physiopathology; D002648:Child; D003071:Cognition; D003072:Cognition Disorders / Q000188:drug therapy / Q000209:etiology* / Q000503:physiopathology; D004305:Dose-Response Relationship, Drug; D004644:Emotions; D004827:Epilepsy / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000077287:Levetiracetam; D008297:Male; D018697:Nootropic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D010889:Piracetam / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D018697:Nootropic Agents; D000077287:Levetiracetam; D010889:Piracetam